Demonstrate clinical and outcomes value of early pathologist-driven comprehensive genomic profiling.
Organizations
Illumina
Providence
+1
National – US
Educate interest holders to advocate for appropriate broad US health insurance coverage of CGP for advanced cancer patients.
Organization
Access to Comprehensive Genomic Profiling Coalition (ACGP)
National – US
Generate patient-reported data on biomarker testing experiences to inform advocacy, policy, and public communications.
Organization
American Cancer Society Cancer Action Network (ACS CAN)
National – US
Global educational campaign focused on HER2 mutations and protein overexpression in NSCLC, with practical learning for multidisciplinary teams on testing, interpretation and integration into care.
Organization
International Association for the Study of Lung Cancer (IASLC)
National – US
International
Advocate for timely biomarker testing through reform of Medicare 14-Day Rule.
National – US
Identify, understand, and close managed-care implementation gaps in biomarker testing to improve receipt of appropriate therapy for all eligible patients, and align payer coverage with clinical evidence.
Organization
Academy of Managed Care Pharmacy (AMCP)
National – US
Develop and disseminate evidence-based clinical practice guidelines for cancer biomarker testing to guide oncology practice and inform coverage decisions.
Organization
American Society of Clinical Oncology (ASCO)
National – US
An interactive 6-session virtual Project ECHO program to build expertise and a regional network to improve Molecular Tumor Board access.
Organization
American Society of Clinical Oncology (ASCO)
International
Quality abstraction registry for outpatient oncology practices to report and measure performance on a set of measures aligned with ASCO's strategic goals and priorities, including ones relevant to biomarker testing.
Organization
American Society of Clinical Oncology (ASCO)
National – US
Advocate for policies supporting appropriate access to high-quality molecular biomarker testing, adequate reimbursement, and role of laboratory professionals in care pathways.
Organization
American Society for Clinical Pathology (ASCP)
National – US
Improve global biomarker testing rates for lung cancer patients through clinical guidelines and provider education.
Organization
International Association for the Study of Lung Cancer (IASLC)
National – US
International
Educational resource explaining PD-L1 immunohistochemistry assays for pathologists, clinicians and other professionals involved in lung cancer diagnosis and treatment.
Organization
International Association for the Study of Lung Cancer (IASLC)
National – US
International
Provide oncology teams with a curated, filterable library of biomarker testing resources.
Organization
Association of Cancer Care Centers (ACCC)
National – US
Define, research, and train a laboratory professional navigator role to coordinate end-to-end biomarker testing.
Organization
American Society for Clinical Pathology (ASCP)
National – US
Illustrate the difference comprehensive biomarker testing makes by depicting hypothetical patient treatment journeys with and without testing.
Organization
American Cancer Society Cancer Action Network (ACS CAN)
National – US
Raise patient and public awareness of biomarker testing through first-person patient stories.
Organization
American Cancer Society Cancer Action Network (ACS CAN)
National – US
Improve accuracy and timeliness of biomarker testing across community and academic cancer centers.
Organization
Association of Cancer Care Centers (ACCC)
National – US
Equip laboratory professionals with strategies to streamline biomarker testing pathways, reduce turnaround delays, and improve care coordination.
Organization
American Society for Clinical Pathology (ASCP)
National – US
Provide protocols for pathologists and lab professionals to completely and uniformly report cancer data.
Organization
College of American Pathologists (CAP)
National – US
International
Improve quality of oncology care through evidence-based treatment pathways and pay-for-performance incentives, including biomarker-guided therapy selection.
National – US